RecruitingPhase 2

The Analgesic Efficacy of Perineural Nalbuphine as an Adjuvant to Bupivacaine in Ultrasound Guided Superficial Cervical Plexus Nerve Block for Thyroid Surgeries. A Double Blinded Randomized Controlled Trial.

Egypt54 participantsStarted 2024-07-15

Plain-language summary

This study aiming to evaluate the analgesic effect of adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries regarding first rescue analgesia in the first twenty-four hours postoperative, VAS score after extubation and complications such as postoperative nausea, vomiting and respiratory depression.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged between 18 to 60 years old of both sexes undergoing elective thyroid surgery. * ASA I and II. Exclusion Criteria: * Patient refusal. * Hypersensitivity or contraindication to nalbuphine or bupivacaine. * Pregnancy or lactating mothers. * Hepatic, cardiac or renal diseases. * Bleeding disorders. * Severe neurological or psychological disorders. * Goitres with retrosternal extension. * Any anatomical disruption in the neck (ex: metastatic lymph nodes).

What they're measuring

time to first rescue analgesia (will be given to VAS score > 4) following surgery in the first 24 hours.

Timeframe: First 24 hours postoperative

Trial details

NCT IDNCT06633068

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-04

Contact for this trial

Sara M Badie, Master degree

0109588821 sarabadie1993@gmail.com

View on ClinicalTrials.gov More Intra and Postoperative Pain Management trials